Table 1. Summary of phosphoproteome changes in the number of phosphorylation sites and proteins.
No. of sites | % | No. of proteins | No. of peptides | No. of sites | % | No. of proteins | No. of peptides | ||
---|---|---|---|---|---|---|---|---|---|
Ratio: B/A<0.5 | Ratio: B/A>2 | ||||||||
pS | 460 | 86.96 | 327 | pS | 536 | 84.68 | 361 | ||
pT | 67 | 12.67 | 62 | pT | 80 | 12.64 | 68 | ||
pY | 2 | 0.38 | 2 | pY | 17 | 2.69 | 15 | ||
Total | 529 | 349 | 553 | Total | 633 | 376 | 672 | ||
Ratio: C/B<0.5 | Ratio: C/B>2 | ||||||||
pS | 89 | 92.71 | 67 | pS | 201 | 92.63 | 154 | ||
pT | 5 | 5.21 | 5 | pT | 16 | 7.37 | 15 | ||
pY | 2 | 2.08 | 2 | pY | 0 | 0.00 | 0 | ||
Total | 96 | 70 | 101 | Total | 217 | 162 | 225 |
Mouse splenic B cells were treated with either anti-IgM (condition B) or TG before the anti-IgM treatment (condition C); untreated B cells were used as the control (condition A).